Navigation Links
Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
Date:9/25/2008

Data Validates Neuroprotective Effect of Quark's New RNAi Product on Dying Retinal Ganglion Cells, a Cause of Blindness in Glaucoma

FREMONT, Calif., Sept. 25 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced QPI-1007 as the Company's first siRNA drug candidate based on its own intellectual property for a host of novel structures having freedom to operate in the siRNA IP space. QPI-1007, which is currently being evaluated in advanced IND enabling preclinical studies as a neuroprotective agent for eye diseases, is the first drug candidate to utilize a novel siRNA structure developed by Quark free of third party IP. The Company is utilizing its proprietary structures and intellectual property to develop additional RNAi drug candidates in its robust pipeline.

Quark has completed studies with QPI-1007 in different animal models of acute and severe optic nerve injury. In collaboration with Prof. Ann Logan of the Division of Medical Sciences, Department of Medicine, University of Birmingham, UK, Quark examined QPI-1007's effectiveness in a model of retinal ganglion cell (RGC) death by optic nerve crush (ONC). In a second study of QPI-1007 in collaboration with Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Universite de Montreal, its effectiveness was examined in a model of RGC death induced by axotomy of the optic nerve. QPI-1007 displayed neuroprotective activity towards RGCs. It significantly protected retinal neurons against delayed degeneration and reduced injury induced RGC death in vivo, the hallmarks of glaucoma and acute injuries such as ischemic optic neuropathy.

Dr. Daniel Zurr, Quark's Chief Executive Officer, stated, "With more RNAi products in human trials than any other company in the industry, Quark has proven its ability to advance siRNA products from discovery to the clinic. The in vivo results of QPI-1007 mark a new era for Quark. We can now rely solely on internally-developed novel compositions and proprietary siRNA structures to develop products that have the potential to provide greater efficacy than current treatments. The breadth of our new structures allows us to selectively pick the most efficacious, stable siRNA structure, which is the most suitable for the specific sequence."

Dr. Logan stated, "QPI-1007 displayed significant neuroprotective activity compared to untreated controls and two different control siRNA molecules in our in vivo model. These results are very exiting. They show that QPI-1007 is a promising drug for ocular neuroprotection."

Dr. Di Polo commented, "The characteristic visual field changes and loss of vision in glaucoma are caused by the selective degeneration of retinal ganglion cells. Our results suggest that QPI-1007 may be an effective neuroprotective therapy for retinal ganglion cells in acute injuries such as non-artheritic ischemic optic neuropathy, and also in slow-progressing chronic optic nerve injuries such as glaucoma. QPI-1007 has the potential to serve an unmet medical need for these indications."

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability to deliver siRNA non invasively to target tissues including the eye, ear, kidney, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified, siRNA molecule to inhibit the expression of the gene RTP801, licensed to Pfizer. In addition, Quark's current clinical pipeline includes AKIi-5, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery, currently in Phase I/IIa clinical trials via systemic delivery and DGFi with open IND for prevention of delayed graft function in kidney transplantation. Based on publicly available information, Quark believes AKIi-5 was the first siRNA delivered systemically in a human clinical trial.

In addition, Quark has a broad pipeline of siRNA drug candidates based on novel structures developed internally. The Company expects to utilize the structures to develop additional RNAi drug candidates.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at http://www.quarkpharma.com
Quark Pharmaceuticals, Inc. The Ruth Group (investors / media)

Juliana Friedman Sara Ephraim / Janine McCargo

+972 89 30 5111 (646) 536-7004 / 7033

jfriedman@quarkpharma.com sephraim@theruthgroup.com

jmccargo@theruthgroup.com


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology:
(Date:2/6/2016)... IL (PRWEB) , ... February 06, 2016 , ... ... recovery phases of eating disorder treatment helps to reduce the frequency and level ... of the Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical ...
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment ... new clinical and scientific initiatives have all marked the last 12 months at ... and CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President Joe ... signed a joint enrollment and degree completion agreement. The agreement, which begins ... degrees at FHU|Dickson. , The agreement allows students to be jointly admitted ...
(Date:2/5/2016)... ... ... The American public tends to feel uncomfortable about drinking recycled waste water ... well water. The recent experience with lead contaminated water in Flint, Michigan, according to ... increasing public acceptance of recycled waste water as drinking water. , The Flint ...
(Date:2/5/2016)... , ... February 05, 2016 , ... At its annual ... Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds former ... the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat has ...
Breaking Medicine News(10 mins):